Diaceutics (LON:DXRX) Reaches New 52-Week High – Time to Buy?

Diaceutics PLC (LON:DXRX)’s stock price reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as GBX 136 ($1.69) and last traded at GBX 136 ($1.69), with a volume of 101158 shares traded. The stock had previously closed at GBX 125.50 ($1.56).

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on DXRX. Canaccord Genuity Group reiterated a “buy” rating and issued a GBX 160 ($1.99) price target on shares of Diaceutics in a research report on Tuesday, December 17th. Canaccord Genuity Group reaffirmed a “buy” rating and set a GBX 160 ($1.99) target price on shares of Diaceutics in a report on Tuesday, December 17th.

Diaceutics Stock Down 0.7 %

The company’s 50 day simple moving average is GBX 120.69 and its 200-day simple moving average is GBX 126.01. The firm has a market capitalization of £114.03 million, a PE ratio of -4,500.00 and a beta of 0.58. The company has a debt-to-equity ratio of 2.93, a quick ratio of 9.92 and a current ratio of 4.85.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.